Search

Displaying results 7351 - 7360 of 7399 in total
  1. Drug

    Quercetin-3'-O-phosphate

    go.drugbank.com/drugs/DB12937
    Investigational

    Quercetin-3'-O-phosphate has been used in trials studying the treatment of Insulin Resistance and Impaired Glucose Tolerance.

  2. Drug

    Troxerutin

    go.drugbank.com/drugs/DB13124
    Investigational

    Troxerutin has been used in trials studying the treatment of Chronic Venous Insufficiency.

    Mixtures: LACORYL® -T GEL, LACORYL® -T GEL
  3. Drug

    Chlorine dioxide

    go.drugbank.com/drugs/DB12453
    Approved

    Chlorine Dioxide has been used in trials studying the treatment of Halitosis.

    Products: Skin N Clean, Ko-c100
  4. Drug

    Methyl pyrrolidone

    go.drugbank.com/drugs/DB12521
    Investigational

    N Methyl Pyrrolidone is under investigation for the treatment of Multiple Myeloma.

    Synonyms: N-methylpyrrolidone, N-methyl-pyrrolidone
  5. Drug

    N-sulfoglucosamine sulfohydrolase recombinant

    go.drugbank.com/drugs/DB12722
    Investigational

    N-sulfoglucosamine sulfohydrolase recombinant is under investigation for the treatment of Mucopolysaccharidosis III and Sanfilippo Syndrome Type A (MPS IIIA).

  6. Drug

    Daporinad

    go.drugbank.com/drugs/DB12731
    Investigational

    Daporinad has been used in trials studying the treatment of Melanoma, Cutaneous T-cell Lymphoma, and B-cell Chronic Lymphocytic Leukemia.

  7. Drug

    Radium Ra-223

    go.drugbank.com/drugs/DB12813
    Investigational

    Radium 223 is under investigation in clinical trial NCT02463799 (Ph 2 Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPC).

  8. Drug

    IPH 1101

    go.drugbank.com/drugs/DB05754
    Experimental

    IPH 1101 is the most advanced drug candidate of the γδ T cell platform … IPH 1101 is a chemically-synthesized structural analog of non-conventional bacterial phosphoantigens which specifically activate the Vγ9Vδ2 T cell subset.

  9. Drug

    CPD 923

    go.drugbank.com/drugs/DB05856
    Experimental

    CPD 923 (N-butylgalactonorjirimycin) is an iminosugar and an analogue of ZavescaTM. It shows efficacy in vivo studies, as well as a favourable pre-clinical tolerability profile.

  10. Drug

    FAV-201

    go.drugbank.com/drugs/DB06130
    Experimental

    FAV-201 is a patient-specific immunotherapy for the treatment of T-cell lymphoma.